Profil bibliographique

Jean‐Charles Nault

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

353Publications signalées

18278Citations signalées

9Affiliations récentes

Institutions déclarées

Délégation Paris 5 Inserm Université Paris Cité Sorbonne Université Université Sorbonne Paris Nord Sorbonne Paris Cité Centre de Recherche des Cordeliers Assistance Publique – Hôpitaux de Paris Hôpital Avicenne

Domaines associés

Hepatocellular Carcinoma Treatment and PrognosisLiver Disease Diagnosis and TreatmentCholangiocarcinoma and Gallbladder Cancer StudiesLiver physiology and pathologyLiver Disease and Transplantation

Publications récentes

2026 articleOpenAlex

Baseline circulating and tumor γδ T cells and early circulating CD8⁺PD1⁺ expansion predict response to Atezolizumab-bevacizumab in HCC

Isabelle Galy–Fauroux, Amna Asif-Laidin, Manon Evain, Joana Gonçalves Araujo et autres

0 citationsClinical Cancer Research

Accès ouvert 2026 articleOpenAlex

Management of rare primary liver cancers: combined hepato-cholangiocarcinoma and fibrolamellar hepatocellular carcinoma

Matteo Gallant, Marie Decraecker, Marianne Ziol, Julien Caldéraro et autres

0 citationsJHEP Reports

Accès ouvert 2026 articleOpenAlex

Laparoscopic or Open Liver Resection Versus Multibipolar Radiofrequency Ablation of HCC Within Milan Criteria on Cirrhosis

Christian Hobeika, François Cauchy, A A Rode, Ephrem Salamé et autres

1 citationLiver International

2026 letterOpenAlex

Reply to: “Genomics-guided therapy in advanced primary liver cancers: A promising yet methodologically challenging landscape”

Claudia Campani, Jean‐Charles Nault

0 citationsJournal of Hepatology

2026 letterOpenAlex

Reply to: Comments on “Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma”

Claudia Campani, Jean‐Charles Nault

0 citationsJournal of Hepatology

Accès ouvert 2026 articleOpenAlex

Clinical predictors of response to atezolizumab/bevacizumab in Child-Pugh B patients with hepatocellular carcinoma

Anne Victoire Odent, Claudia Campani, Mohamed Bouattour, Yann Touchefeu et autres

0 citationsJHEP Reports

2026 articleOpenAlex

Long-term Survival and Cure Fraction in Patients with Advanced Hepatocellular Carcinoma under Immunotherapy in Randomized Controlled Trials and Real-world Data

Claudia Campani, Ju Hyun Shim, Mohamed Bouattour, Yann Touchefeu et autres

1 citationClinical Cancer Research

Accès ouvert 2026 reviewOpenAlex

Radiological Loco‐Regional Treatments for Cholangiocarcinoma: A Systematic Review of the Literature

D C Pallas, Claudia Campani, Olivier Sutter, Pierre Nahon et autres

0 citationsLiver International

Accès ouvert 2025 reviewOpenAlex

Cholangiocarcinoma 2026: status quo, unmet needs and priorities

Jesús M. Bañales, Pedro M. Rodrigues, Silvia Affò, Jesper B. Andersen et autres

67 citationsNature Reviews Gastroenterology & Hepatology

Accès ouvert 2025 articleOpenAlex

Targeting ATR to overcome cisplatin resistance in hepatoblastoma

Pierre Morel-Ribeiro, Marianna Cornet, Jill Pilet, Amna Asif-Laidin et autres

1 citationJournal of Hepatology

Accès ouvert 2025 preprintOpenAlex

Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma

Jean‐Charles Nault, Théo Z. Hirsch, Waqar Arif, Sandrine Imbeaud et autres

0 citationsmedRxiv

Accès ouvert 2025 articleOpenAlex

35P Non-invasive detection and prediction of esophageal varices and liver decompensation events in AtezoBev-treated HCC patients through machine and foundation-model deep learning

Asier Rabasco Meneghetti, C. Campani, Charles Roux, Zunamys I. Carrero et autres

0 citationsESMO Real World Data and Digital Oncology

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.